Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Targeting Gene Fusions in Supratentorial Ependymoma: A Personalized Medicine Approach

EF 2025-26

Résumé
Background: Supratentorial ependymoma (sEPN) is a highly aggressive pediatric brain tumour driven predominantly by the ZFTA-RELA fusion. Currently, no systemic therapy for sEPN is available, and treatment relies on surgery and radiation therapy in young children, causing significant neurocognitive deficits. Preliminary data of 110 sEPN tumours from the Ramaswamy Lab demonstrate that ZFTA-RELA is the sole oncogenic driver in most cases, highlighting it as an ideal therapeutic target. Antisense oligonucleotides (ASOs) have recently made significant strides in becoming a viable clinical approach, with many ASO-based trials currently underway. Critically, ASOs’ high degree of specificity enables precise targeting of oncogenic fusion junctions only present in malignant cells, maximizing specificity and minimizing off-target effects. Hypothesis: ASO-mediated targeting of undruggable fusion transcripts is a rational approach to the treatment of sEPN. Aims: 1) ASO candidates will be designed, screened, and optimized based on accessibility, secondary structure, and fusion-specificity. 2) ZFTA-RELA knockdown efficiency, as well as changes in proliferation, apoptosis, viability and off-target effects will be compared between ASO candidates in sEPN patient-derived cell lines. 3) Intrathecal delivery of ASOs will be tested in orthotopic ZFTA-RELA patient-derived xenograft mice by evaluating tumour burden, survival, and molecular assays from (2) on tumour tissue. Conclusion: This study delineates a rational ASO-mediated strategy to target the sole drivers of sEPN, potentially improving patient survival while reducing the social and economic disease burden. This study also provides proof of concept for designing ASOs targeting other fusions within EPN and other cancers.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573306
Name
Tourigny Noah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Gene Fusions in Supratentorial Ependymoma: A Personalized Medicine Approach
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antisense Oligonucleotides; Ependymoma; Gene Fusion Oncogenes; Patient-Derived Cell Lines; Patient-Derived Xenograft Models; Pediatric Brain Tumours; Preclinical Therapeutic Development; Rna-Targeting Therapeutics; Translational Neuro-Oncology; Zfta-Rela Fusion
Abstract
Background: Supratentorial ependymoma (sEPN) is a highly aggressive pediatric brain tumour driven predominantly by the ZFTA-RELA fusion. Currently, no systemic therapy for sEPN is available, and treatment relies on surgery and radiation therapy in young children, causing significant neurocognitive deficits. Preliminary data of 110 sEPN tumours from the Ramaswamy Lab demonstrate that ZFTA-RELA is the sole oncogenic driver in most cases, highlighting it as an ideal therapeutic target. Antisense oligonucleotides (ASOs) have recently made significant strides in becoming a viable clinical approach, with many ASO-based trials currently underway. Critically, ASOs’ high degree of specificity enables precise targeting of oncogenic fusion junctions only present in malignant cells, maximizing specificity and minimizing off-target effects. Hypothesis: ASO-mediated targeting of undruggable fusion transcripts is a rational approach to the treatment of sEPN. Aims: 1) ASO candidates will be designed, screened, and optimized based on accessibility, secondary structure, and fusion-specificity. 2) ZFTA-RELA knockdown efficiency, as well as changes in proliferation, apoptosis, viability and off-target effects will be compared between ASO candidates in sEPN patient-derived cell lines. 3) Intrathecal delivery of ASOs will be tested in orthotopic ZFTA-RELA patient-derived xenograft mice by evaluating tumour burden, survival, and molecular assays from (2) on tumour tissue. Conclusion: This study delineates a rational ASO-mediated strategy to target the sole drivers of sEPN, potentially improving patient survival while reducing the social and economic disease burden. This study also provides proof of concept for designing ASOs targeting other fusions within EPN and other cancers.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tourigny, Noah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~